News Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Jun 28, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) today announced that it entered into an amended agreement related to its...
- Jun 27, 2019Enteris BioPharma’s “Feasibility-to-Licensing” Partner, Cara Therapeutics, Initiates Second Pruritus Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™
Boonton, NJ – June 27, 2019 – Enteris BioPharma, Inc. a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, congratulates...
- Jun 27, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening...
- Jun 27, 2019
Acerus Pharmaceuticals Corporation ("Acerus") (TSX:ASP) today announced the voting results from its annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario. The total number of...
- Jun 26, 2019–Reached Agreement with FDA on Regulatory Package for NDA Submission Utilizing the 505(b)(2) Expedited Regulatory Pathway— — TADFIN is a First Novel Combination Formulation of Tadalafil and Finasteride for the Treatment of BPH with NDA Submission Anticipated in Summer of 2020–
MIAMI, June 26, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...